INB-100
Leukemia (post-Hematopoietic Stem Cell Transplant)
Phase 1Active, dose escalation
Key Facts
Indication
Leukemia (post-Hematopoietic Stem Cell Transplant)
Phase
Phase 1
Status
Active, dose escalation
Company
About IN8bio
IN8bio is a leader in the clinical development of gamma-delta T cell therapies, a promising but challenging class of cellular immunotherapy. The company's core innovation is its DeltEx™ platform, which enables the genetic engineering and scalable manufacturing of γδ T cells, including its proprietary Drug Resistant Immunotherapy (DRI) approach designed to work in tandem with chemotherapy. With multiple clinical-stage assets, most notably INB-400 in a Phase 2 trial for glioblastoma, IN8bio is strategically positioned to address significant unmet needs in oncology, though its success hinges on clinical validation and navigating a complex competitive and financial landscape.
View full company profile